Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.72 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863233 | 0.86 | HDAC8 (0.62) | EPHX2MAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL6920040 | 0.85 | ABL1 (0.62) | EPHX2MAPTSMN1; SMN2GAAKMT2A | |
| SCHEMBL28195198 | 0.84 | PRKDC (0.55) | EPHX2MAPTGAAMEN1LMNA | |
| SCHEMBL3936504 | 0.84 | EPHX2 (1.00) | EPHX2MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL3994030 | 0.82 | EPHX2 (0.70) | EPHX2MAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL4548170 | 0.81 | ALDH1A1 (0.63) | EPHX2MAPTSMN1; SMN2GAALMNA | |
| SCHEMBL11555827 | 0.81 | EPHX2 (1.00) | EPHX2MAPTMEN1HTTKMT2A | |
| SCHEMBL13634099 | 0.81 | EPHX2 (0.75) | EPHX2MAPTSMN1; SMN2GAAKMT2A | |
| SCHEMBL4180664 | 0.81 | MAPT (0.65) | EPHX2MAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL4922234 | 0.80 | MAPT (0.73) | EPHX2MAPTSMN1; SMN2GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125997-B2 | Differential tumor cytotoxicity compounds and compositions | IRM LLC (BM) | 2006-10-24 | — | — | US | disclosed |
| US-20040132786-A1 | Differential tumor cytotoxicity compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132786-A1 | Differential tumor cytotoxicity compounds and compositions | MIF, FOXM1, MYADM | EPHX2 1102/4885MAPT 4643/4885SMN1; SMN2 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.